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A growing body of research suggests that fructose 1,6-bisphosphatase (FBPase) might be involved in
regulation of cell mortality/survival. However, the precise role of FBPase in the process remains
unknown. Here, we show for the ﬁrst time that in HL-1 cardiomyocytes, inhibition of glycogen syn-
thase kinase-3 results in translocation of FBPase to mitochondria. In vitro experiments demonstrate
that FBPase reduces the rate of calcium-induced mitochondrial swelling, affects ATP synthesis and
interacts with mitochondrial proteins involved in regulation of volume and energy homeostasis. We
suggest that FBPase might be engaged in a regulation of cell survival by inﬂuencing mitochondrial
function.
Structured summary of protein interactions:
FBPase physically interacts with VDAC2, Vdac3, ATP synthase subunit beta, Slc25a5, ATP synthase sub-
unit alpha, Histone cluster 1, H1d, Histone H2A, Histone H4 and Histone H3 by afﬁnity chromatography
technology (View interaction)
FBPase physically interacts with ATP synthase subunit b, ATP synthase subunit a, ADP/ATP translocase 1,
ADP/ATP translocase 2 and VDAC2 by cross-linking study (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In vertebrate tissues, two distinct isozymes of fructose 1,6-bis-
phosphatase (FBPase; EC 3.1.3.11) are present [1]. The liver isozyme
is a regulator of glucose synthesis from carbohydrate precursors.
Muscle FBPase is expressed in all vertebrate cells and a growing
body of research suggests that its physiological function goes
beyond participation in the synthesis of glucose/glycogen from
non-carbohydrates.
Previouslywe showed that,muscle FBPase is found inside thenu-
clei and we suggested that this localization accompanies the cell’s
potential to divide [2,3]. We showed that, in HL-1 cardiomyocytes,
FBPase disappearance from the nuclei coincided with a signiﬁcant
increase of the cells mortality [3]. Proteomic studies to date imply
that FBPase might be involved in apoptosis [4,5]. However, the data
are still few and inconsistent, and the precise role of FBPase in the
process remains unknown.
Glycogen synthase kinase-3 (GSK3) has been recognized as a
multi-functional kinase and a key element of a range of cellularchemical Societies. Published by E
nimal Molecular Physiology,
law, Poland. Fax: +48 71 375
).processes, including glycogen biosynthesis, apoptosis or necrosis.
In the heart, the b isoform of GSK3 acts as an inhibitor of hypertro-
phic signaling [6], where suppression of the enzyme reduces the
ischemia/reperfusion injury through a mechanism dependent on
the mitochondria [7]. This suggests a crucial role of GSK3b in
cardioprotection.
Our evidence points to FBPase as a target of the GSK3 pathway.
We show that, in HL-1 cardiomyocytes, inhibition of GSK3 activity
results in translocation of FBPase to mitochondria. In vitro experi-
ments demonstrate that FBPase reduces the rate of calcium-induced
mitochondrial swelling and affects ATP synthesis, interacting with
mitochondrial proteins involved in regulation of membrane
permeability.
This is the ﬁrst experimental evidence that muscle FBPase local-
izes on mitochondria and might be an important link between the
GSK3 activity, mitochondrial function and cardiac cell survival dur-
ing prolonged, high-intensity work.
2. Materials and methods
Unless stated otherwise, all chemicals were from Sigma-Aldrich
and were of the cell culture grade. HL-1 cardiomyocytes were pre-
sented by Dr. W.C. Claycomb (Louisiana State University Health
Science Center, New Orleans, LA, USA) [8].lsevier B.V. All rights reserved.
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The HL-1 cells were cultured as described before [3]. After
reaching 70–80% conﬂuency the cells were incubated for 2 h at
37 C in the culture medium supplemented with GSK3 inhibitors:
10–20 mM LiCl or 2–5 lM SB216763. In another set of experi-
ments, HL-1 cells were incubated for 1 h in the culture medium
supplemented with 0.3 mM CaCl2 either alone or with 0.01 mM
calcium ionophore A23187. After treatment, they were prepared
for immunocytochemistry.
2.2. Immunocytochemistry
The HL-1 cells were stained with rabbit anti-muscle FBPase pri-
mary antibodies (abs; 2 lg/ml) and TRITC-conjugated secondary
abs. To counterstain mitochondria, cultured cells were incubated
before ﬁxation with 5 lg/ml rhodamine 123. In co-localization
experiments, where anti-cytochrome c (BioVision) or anti-GSK3
pS9 (Millipore) abs developed in rabbit were used, FBPase was lo-
cated with abs developed in mouse. The detailed procedures are
presented in Supplementary data 1. The antibodies against rabbit
and mouse muscle FBPase were produced, puriﬁed and tested as
we described before [2,3].
For observation in transmission electron microscopy (TEM), the
ultra-thin sections of glutaraldehyde-ﬁxed cells were incubatedwith
anti-FBPase abs andwith secondary abs conjugated with 10 nm gold
particles. To check the statistical importance of alternate gold
particles distribution the Wald–Wolfowitz non-parametric test was
used. A detailed procedure is described in Supplementary data 2.
2.3. Cell transfection with FBPase
Transfection of cells with 1.5–4 lg of TRITC-labeled muscle
FBPase was performed as described previously [9], and in the
presence or in the absence of GSK3 inhibitors (LiCl or SB216763).
After transfection, the cells were immediately examined using
the confocal microscope. As a control, cells were transfected with
TRITC-conjugated BSA.
2.4. Isolation of mitochondria and mitoplast preparation
The HL-1 cells mitochondria were puriﬁed onto sucrose gradi-
ent [10]. The mitochondrial pellet was lysed, and the lysate was
used for detection of FBPase with mass spectrometry and Western
blot. Mitoplast was obtained by digitonin method [11].
2.5. Measurement of mitochondrial swelling
Mitochondrial volume measurements were performed using an
HP 8452A spectrophotometer. Swelling of the organelles was iden-
tiﬁed as an abrupt decrease in light absorbance at 540 nm. A de-
tailed procedure is described in Supplementary data 3.
2.6. Activity measurement
FBPase activity was assayed as described by [12]. Ca2+ is a
strong inhibitor of muscle FBPase [13] and mitochondria are one
of the major cellular calcium stores. To avoid Ca2+ efﬂux into the
assay mixture, for the measurements of FBPase activity associated
with mitochondria an intact organella, puriﬁed onto sucrose gradi-
ent, were used. Consequently, the obtained activity is believed to
represent the activity of the enzyme’s activity associated with
the outer mitochondrial membrane. To verify the presence of
FBPase in the intramembrane space, its activity was measured in
a mitoplasts suspension. All measurements were repeated in the
presence of a calcium chelator, 1 mM EGTA.2.7. Identiﬁcation of FBPase-interacting proteins
The SB216763-treated HL-1 cells were incubated with NHS-
SS-Diazirine cross-linker. Isolated mitochondria were lysed and
resolved by 6% SDS–PAGE. The obtained gels were silver-stained
or used for Western blot. The protein bands from silver-stained
gel, corresponding to those detected with anti-FBPase antibodies
in the reference Western blot, were excised and analyzed commer-
cially by ESI-MS. For detailed procedure see Supplementary data
4.1. Alternatively, an afﬁnity chromatography and Sepharose-
FBPase column was used, followed by MS analysis (Supplementary
data 4.2).
2.8. Competition assay
Isolated mitochondria were incubated for 30 min on ice with
different amounts of muscle FBPase (ﬁnal concentration:
0–31 lg/ml) and BSA (31–0 lg/ml) such that the ﬁnal amount of
added protein was kept constant. Mitochondria were pelleted,
ﬁxed in 4% paraformaldehyde and incubated with anti-GSK3b
pS9 antibody or antibody staining all forms of GSK3 b (phosphory-
lated and dephosphorylated; anti-total GSK3b) and with FITC-
conjugated secondary abs. After rinsing the mitochondria in buffer
with addition of 250 mM sucrose and brief pelleting, droplets of
the organella were placed on microscopic slides and the intensity
of green ﬂuorescence of at least 60 mitochondria was measured
with confocal microscopy. The effect of lithium on localization of
total GSK3b and GSK3b pS9 on mitochondria is presented in
Supplementary data 8.
2.9. ATP measurement
Changes in ATP synthesis by intact mitochondria that occur in
the presence of calcium and muscle FBPase were monitored by
the luminescent method as it is described in Supplementary data 5.
2.10. Statistical analysis
Collected data was analyzed using GraFit 4 software. Results are
expressed as mean and standard deviation (S.D.). For an evaluation
of statistical signiﬁcance a Student’s t-test was used. A probability
of p < 0.05 was considered to represent a signiﬁcant difference.3. Results and discussion
3.1. FBPase localizes on mitochondria after GSK3 inhibition
Muscle FBPase seems to be expressed in all vertebrate cells. Its
relatively low expression and the active nucleo-cytoplasmic shut-
tling might suggest that muscle FBPase, in addition to its metabolic
role, is also involved in other cellular processes. The existing pro-
teomic studies [4,5], demonstrating changes of FBPase expression
during apoptosis suggest that FBPase might be involved in the
modulation of cell mortality/survival.
Treatment of HL-1 cardiomyocytes with GSK3 inhibitors
reduced the amount of nuclear FBPase (Fig. 1A–C). While applica-
tion of SB216763 resulted in a complete withdrawal of FBPase
from the compartment, the effect of LiCl was evidently weaker.
However, nuclear transport of FBPase requires phosphorylation of
the enzyme [3]. Thus the limited effectiveness of LiCl in removing
FBPase from the nucleus might result from an indirect effect of
phosphatase inactivation by LiCl [14].
The most prominent effect of GSK3 inhibition was the presence
of FBPase on subcellular structures, which we assumed to be mito-
chondria, in about 88% of cells. We used rhodamine 123 to conﬁrm
Fig. 1. Localization of FBPase in HL-1 cardiomyocytes. (A) In basal conditions. (B) After treatment with 20 mM LiCl. (C) After treatment with 5 lM SB216763. (D–F)
Localization of FBPase (E) on rhodmine 123-stained mitochondria (D); F – merged images) after LiCl treatment. (G and H) Structure of mitochondria in control HL-1 cells (G)
and after treatment with GSK3 inhibitor (H). Bar = 20 lm.
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FBPase and mitochondria were basically superimposable. Interest-
ingly, majority of GSK inhibitor-treated cells displayed fragmenta-
tion of the mitochondrial network (Fig. 1C, G and H).
3.2. FBPase interacts with mitochondria in vivo
Transfection of HL-1 cells with ﬂuorescently-labeled FBPase in
the presence of the GSK3 inhibitor revealed the interactions of
FBPase with mitochondria in vivo (Fig. 2C). In the absence of the
inhibitor, TRITC-labeled FBPase accumulated in the nucleo-
cytoplasmic compartment, as demonstrated before [9]. Neverthe-
less, careful screening of the cells transfected with FBPase inFig. 2. Transfection of HL-1 cells with ﬂuorochrome-labeled proteins. (A and B): In abo
localizes as granules aligned along with ﬁlamentous mitochondria. Image B shows enlarge
mitochondria of granular morphology after inhibition of GSK3. (D) A fragment of GSK
diffused cytoplasmic localization. (E) Counterstaining with rhodamine 123. (F) Merged icontrol conditions revealed that in about 8% of the cells FBPase
binds to mitochondria (Fig. 2A and B). Structure of mitochondria
in these cells was ﬁlamentous rather than globular, implying that
FBPase binds to mitochondria prior to their ﬁssion. TRITC-labeled
BSA, introduced as control into cells treated with GSK3 inhibitor,
revealed a diffused cytoplasmic localization (Fig. 2D–F).
3.3. Electron microscopy reveals intramitochondrial presence
of FBPase
In GSK3 inhibitor-treated cells, the gold particles localized
predominantly in a direct neighborhood of mitochondrial surface,
in a distance 630 nm (Fig. 3A), where the distance represents anut 8% of the control HL-1 cells, transfected with TRITC-labeled FBPase, the protein
d fragment of A. (C) Localization of TRITC-labeled FBPase on rhodamine 123-stained
3-inhibitor-treated HL-1 cell transfected with TRITC-labeled BSA which reveals a
mages. Bar = 20 lm.
Fig. 3. TEM analysis of FBPase association with mitochondria. (A) Distribution of gold particles considering their distance to mitochondria. (B) A weak immunogold reaction
observed within mitochondria in the absence of GSK3 inhibitor. Bar = 1 lm.
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secondary ab lengths. Using the Wald–Wolfowitz non-parametric
test, we determined that the relocation of gold particles into close
proximity of mitochondria was statistically signiﬁcant, leaving
<3.4% chance to be a matter of coincidence. We also found a weak
immunogold reaction inside the mitochondria, both in the pres-
ence and in the absence of a GSK3 inhibitor, but not in a control
lacking anti-FBPase antibodies (Fig. 3B).
3.4. The presence of FBPase in mitochondria correlates with GSK3
inhibition
A Western blot analysis demonstrated that FBPase was present
in mitochondrial extracts from the inhibitor-treated HL-1 cardio-
myocytes but absent in the mitochondria of control cells (Supple-
mentary data 6).
The activity of FBPase bound to intact mitochondria isolated
from the GSK3 inhibitor-treated cells represented about 20% of
the total cellular FBPase activity, corresponding to about 2.5 lg of
FBPase per mg of mitochondrial proteins. Activity of the enzyme
in the mitochondrial fraction isolated from control cells was unde-
tectable. Following the removal of the outer mitochondrial
membrane, 29% of the initial mitochondrial activity of FBPase re-
mained, indicating that the enzyme associates not only with the
outer but also with the inner membrane.Fig. 4. Co-localization of FBPase with mitochondrial proteins after GSK3 inhibitor treatm
FBPase (B) on mitochondria of HL-1 cells treated with LiCl. (C) merged images. (D and E) C
treatment. (F) Merged images. Bar = 20 lm.3.5. FBPase competes with GSK3b for binding to mitochondria
GSK3b is known to reside on the outer mitochondrial membrane
(OMM), where it modulates interactions of the voltage-dependent
anion channel (VDAC) with apoptosis-regulating proteins [15].
Co-localization of FBPase with GSK3 (and therefore, with VDAC)
might provide a valuable clue as to themitochondrial role of FBPase.
Immunostaining of lithium-treated HL-1 cells with anti-FBPase
abs and antibody targeted to phosphorylated serine 9 of GSK3b
(lithium increases the amount of GSK3b phosphorylated on a
serine 9 [14]) demonstrated only partial overlapping of ﬂuorescence
(Fig. 4A–C). However, the competition experiment revealed that in
the presence of increasing amounts of puriﬁed muscle FBPase, but
not BSA, the binding of anti-total GSK3b as well as anti-GSK3b pS9
antibodies to mitochondria decreases, suggesting that FBPase and
GSK3 bind to the same site on the mitochondria (Fig. 5).
In untreated HL-1 cardiomyocytes, mitochondria are mostly or-
ganized in ﬁlamentous structures. The fragmented mitochondrial
morphology that we noticed after GSK3 inhibition is understood
to correlate with apoptotic changes. To test if the observed mito-
chondrial network disintegration accompanies apoptotic events,
we searched for the cytochrome c localization in HL-1 cells prein-
cubated with GSK3 inhibitors. Unexpectedly, even after 24 h of
inhibitor treatment cytochrome c remained in the mitochondria,
indicating a lack of apoptosis (Fig. 4D–F). Withdrawal of theent of cardiomyocytes. (A–C) Co-localization of GSK3 phosphorylated on S9 (A) and
o-localization of cytochrome c (D) and FBPase (E) in cardiomyocytes after SB216763
Fig. 5. Accumulation of GSK3b on mitochondria after preincubation of HL-1 cells with different concentrations of muscle FBPase. The accumulation of GSK3 phosphorylated
at S9 (A) and total GSK3b (B) is signiﬁcantly weaker in the presence of FBPase (p < 0.05). Each value represents the mean and S.D. of at least 60 individual measurements.
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ment of FBPase from mitochondria and its slow return to the
nucleus. These results imply that in HL-1 cardiomyocytes, mito-
chondrial ﬁssion is not necessarily associated with apoptosis.
3.6. FBPase reduces Ca2+-induced mitochondrial swelling
Since binding of FBPase to mitochondria apparently did not
coincide with cardiomyocyte apoptosis, we decided to test its
pro-survival potential.
It has been demonstrated that mitochondria-dependent cell
death results from the opening of permeability transition pores
(PTP), followed by a loss of mitochondrial transmembrane poten-
tial. It is also well accepted that agents blocking PTP opening pro-
tect the mitochondria from matrix swelling and the OMM rupture.
If FBPase accumulation on the mitochondria was to contribute to
cell survival, it was plausible that the enzyme would act through
interference with the PTP opening.
Results of our experiment have shown that elevated calcium – a
well known PTP opening inducer and one of the most potent induc-
ers of apoptotic and necrotic cell death – promoted the binding ofFig. 6. The effect of calcium on FBPase localization. A 45-min incubation of HL-1 ce
mitochondria (B) of HL-1 cardiomyocytes. (C) Merged images. (D) Localization of FBPaseFBPase to mitochondria (Fig. 6). Addition of calcium together with
calcium ionophore resulted in a distortion in the ﬁlamentous shape
of the mitochondria.
Determination of the volume changes of the mitochondria iso-
lated from HL-1 cells and re-suspended in a swelling buffer dem-
onstrated that 0.3 mM Ca2+ induces an abrupt increase in
baseline swelling of the organelles, as measured by fall in light
absorbance at 540 nm (Fig. 7A). Pretreatment of mitochondria with
1.5 lg/ml of pure muscle FBPase reduced the rate of fall in absor-
bance, suggesting a partial inhibition of Ca2+-induced swelling.
Addition of the same amount of BSA had no marked effect on light
absorbance. Pre-incubation of mitochondria with cyclosporin A
(inhibitor of PTP opening) almost completely inhibited the Ca2+-
induced swelling (Fig. 7A). This indicates that the changes in light
absorbance observed during this test were due to the opening of
the PTP. This suggests that FBPase may be involved in delay of
mitochondrial swelling, by desensitizing the PTP to Ca2+.
Amodest rise in intracellular [Ca2+] is essential for stimulation of
glycolysis and oxidative phosphorylation. Ca2+ could also be an
agent inducing cardiac hypertrophy in response to a chronic in-
crease in workload. Although it could be beneﬁcial as an adaptationlls with CaCl2 and calcium ionophore results in accumulation of FBPase (A) on
in control conditions. Bar = 20 lm.
Fig. 7. The effect of FBPase on mitochondrial function. (A) Effect of FBPase on Ca2+-induced mitochondrial swelling. The swelling was monitored via the decrease in light
absorbance at 540 nm and expressed as a percentage of baseline swelling of untreated mitochondria. From the left: untreated mitochondria – control, mitochondria treated
with: 0.3 mM Ca2+, 1.5 lg/ml of muscle FBPase and 0.3 mM Ca2+, cyclosporin A and 0.3 mM Ca2+, 1.5 lg/ml BSA and 0.3 mM Ca2+. (B) Effect of muscle FBPase (1.5 lg/ml) and
0.3 mM Ca2+ on ATP synthesis by mitochondria. ATP synthesis is expressed as a percentage of that in control conditions, i.e. in the absence of Ca2+ and FBPase. Each value
represents the mean and S.D. of at least three individual experiments.
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associated with a number of cardiovascular diseases.
In the development of hypertrophy, a calcineurin pro-hypertro-
phic signaling, activated by a sustained elevation of intracellular
[Ca2+], results in inhibition of GSK3, a known anti-hypertrophic
agent in cardiac myocytes [6,16]. During such Ca2+ elevation, mito-
chondria accumulate the ion rapidly, which might induce their
swelling and rupture [17]. Therefore, the association of FBPase
with mitochondria stimulated by GSK3 inhibition and by calcium
and the blocking of mitochondrial swelling might be a mechanism,
which adapts cardiomyocytes to calcium overload during pro-
longed, high-intensity work, without progression to heart failure
and death.
3.7. FBPase interacts with mitochondrial proteins
To ﬁnd FBPase-interacting proteins in the mitochondria, two
different approaches, followed by MS analysis, were used. First,
we performed an in vivo cross-linking of FBPase with its binding
partners in SB216763-treated HL-1 cells. The second approach
was the afﬁnity chromatography. Results of the experiments
revealed FBPase interactions with both mitochondrial membrane-
and matrix-related proteins. Among them were ATP synthase, ANT
and VDAC2 and all representative members of the histone family of
proteins (Table 1; Supplementary Fig. 1).
Inhibition of GSK3b prevents PTP opening [18], reduces mito-
chondrial depolarization (Supplementary data 7) and the active
enzyme increases cardiac mitochondrial membrane permeability
by phosphorylating VDAC2 [7]. In spite of claims that VDAC is not
a component of PTP, it could act as a transducer of signals which
increase the probability of PTP opening [19]. FBPase competesTable 1
FBPase-interacting proteins of interest detected with afﬁnity chromatography and
subsequent mass spectrometry analysis.
Protein Score Sequence
coverage (%)
Mass
(Da)
Accession
number
Histone H3 1500 37 15077 A1L0U3
Histone H4 1352 52 11360 B2RTM0
Histone H2B 835 61 14900 D3Z004
Histone H2A 579 57 14087 B2RWH3
Histone cluster 1, H1d 501 28 22086 Q149Z9
ATP synthase subunit beta 574 42 56300 AAH37127
ATP synthase subunit alpha 358 19 54675 D3Z6F5
Slc25a5 (ANT-like protein) 218 18 33138 Q545A2
VDAC2 134 6 32327 P81155
Vdac3 72 3 30753 Q60931with GSK3 for the binding to mitochondria in vitro and VDAC2 is
among the interaction partners of FBPase. Thus, the protective
mechanism of FBPase against mitochondrial swelling might be, at
least partially, explained by amodel inwhich FBPase competeswith
active GSK3b for association with VDAC2 to reduce the OMM
permeabilization. Alternatively, upon GSK3 inhibition, mitochon-
drial FBPase could transduce the pro-survival signals to other
peripheral PTP-sensitivity regulators. Apart from VDAC, FBPase
could potentially interact with ATP synthase and ANT. All of the
proteins participate in energy and calcium homeostasis and might
be engaged – directly or indirectly – in modulation of PTP opening
and subsequent cell death, and as such might be a target of the
FBPase action.
VDAC is a protein with an extra-mitochondrial domain, hence its
interactionswith FBPaseduringGSK3 inhibition is not controversial.
The high probability that ATP synthase and ANT are among FBPase-
interacting proteins indicates that FBPase is translocated to the
inter-membrane space following GSK3 inhibition. This is quite
unexpected, but our ﬁnding is substantiated by a TEM analysis and
by detection of FBPase activity associatedwith the innermembrane.
However, since interactions of inactive, serine-9-phosphory-
lated GSK3b, with the components of PTP, especially with ANT, is
considered to be cardioprotective [20], the competition of FBPase
for binding to mitochondria not only with active but also with
inactive GSK3b is confusing. Thus, further investigation is needed
to clarify the relationship between mitochondrial FBPase and
GSK3.
3.8. FBPase inﬂuences mitochondrial ATP synthesis
Our assumption that mitochondrial ATP synthase and/or ANT
are targets of FBPase has been conﬁrmed by the experiment show-
ing that muscle FBPase (1.5 lg/ml) signiﬁcantly elevated the level
of ATP synthesized in the cardiomyocytic mitochondria. A patho-
logical concentration of calcium ions decreased ATP production
more than two-fold (Fig. 7B). Incubation of mitochondria in the
presence of both FBPase and Ca2+ cancelled the inhibitory effect
of the ion, and the level of ATP was similar to that measured in con-
trol conditions.
It has been demonstrated that depolarization of the mitochon-
dria triggered by high [Ca2+] is followed by a decrease in ATP syn-
thesis, leading to cell death. It appears that, in cardiomyocytes, the
probability of such depolarization could be (at least locally)
reduced through the action of FBPase, which prevents mitochon-
drial dysfunction not only by interfering with the Ca2+-induced
PTP opening but also by stimulating ATP synthesis. This might ex-
plain a quite unexpected competition between FBPase and inactive
A. Gizak et al. / FEBS Letters 586 (2012) 13–19 19form of GSK3b for binding to mitochondria: inactivation of GSK3b
protects ATP from mitochondrial hydrolysis, whereas FBPase may
be involved in sustaining of ATP synthesis.
Among the FBPase-interacting mitochondrial proteins are sev-
eral DNA-binding proteins, such as histones. This is in line with a
still controversial hypothesis that histone-like proteins are present
in the mitochondrial matrix, where they form nucleosome-like
structures [21]. Our results might, therefore, suggest that FBPase
modulates the cellular response to stress signals also by affecting
the nucleosome-related processes.
Regardless of the precise mechanisms involved, this is the ﬁrst
experimental evidence that muscle FBPase localizes on mitochon-
dria and – as a part of a GSK3 signal transduction system – might
be engaged in a regulation of cardiomyocyte survival by inﬂuenc-
ing mitochondrial function.
Results of our preliminary studies suggest that in HL-1 cells
with shRNA-down-regulated FBPase, mitochondria are more sus-
ceptible to depolarization (Supplementary data 9).
Further study of stress signaling in cardiomyocytes which lack/
overexpress different forms of muscle FBPase, including inactive
and non-phosphorylated form, is currently in progress.
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